GlassScriptPhysician profile
Christopher B Normile
NPI 1578530945
$9,481.44
in general payments reported to CMS, 2019-2025
43 companies · $1,288 in 2025
The $1,288 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $314 · 2021: $1,532 · 2022: $2,127 · 2023: $2,387 · 2024: $1,524 · 2025: $1,288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,184 · Entertainment: $15.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,183.90 |
| Entertainment | $15.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,882.66 | 2021-2025 | |
| Lilly USA, LLC | $1,152.81 | 2019-2025 | Mounjaro, Emgality, Zepbound |
| Astrazeneca Pharmaceuticals LP | $882.53 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $834.00 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $817.99 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $718.14 | 2019-2025 | |
| Amgen INC. | $543.18 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.73 | 2020-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $201.34 | 2022-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $196.24 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $184.61 | 2019-2025 | Capvaxive, Gardasil 9, Enflonsia |
| Teva Pharmaceuticals USA, INC. | $183.09 | 2021-2023 | Austedo |
| Exact Sciences Corporation | $156.73 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $137.72 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $125.47 | 2019-2023 | Xarelto |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Normile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.